このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

2018年8月31日 更新者：Takeda

An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV

The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who have Crohn's disease. This study will look at mucosal healing in people who take vedolizumab.

The study will enroll approximately 100 patients and will be conducted in 2 Parts. Part A will consist of a 26-week treatment period and all participants will receive vedolizumab 300 mg intravenously (IV) on Day 1 and at Weeks 2, 6, 14 and 22. Part B will consist of a 26-week extension treatment period and all participants will receive vedolizumab 300 mg IV at Weeks 30, 38, and 46.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 70 weeks for Parts A, B and 18-Week Follow-up combined. Participants will make multiple visits to the clinic. All participants included in the study will also have a 6 month safety follow-up telephone call following his/her last dose of study drug.

研究の種類

介入

入学 (実際)

101

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

  • アメリカ
    • California
      • La Jolla、California、アメリカ
    • Connecticut
      • Hamden、Connecticut、アメリカ
    • Florida
      • Gainesville、Florida、アメリカ
      • Inverness、Florida、アメリカ
      • Maitland、Florida、アメリカ
      • Miami、Florida、アメリカ
      • Winter Park、Florida、アメリカ
    • Georgia
      • Macon、Georgia、アメリカ
      • Suwanee、Georgia、アメリカ
    • Kansas
      • Topeka、Kansas、アメリカ
    • Louisiana
      • Baton Rouge、Louisiana、アメリカ
    • Maryland
      • Columbia、Maryland、アメリカ
    • Massachusetts
      • Boston、Massachusetts、アメリカ
    • Michigan
      • Ann Arbor、Michigan、アメリカ
    • Missouri
      • Saint Louis、Missouri、アメリカ
    • New York
      • Manhasset、New York、アメリカ
      • Poughkeepsie、New York、アメリカ
    • North Carolina
      • Winston-Salem、North Carolina、アメリカ
    • Ohio
      • Cleveland、Ohio、アメリカ
    • Oklahoma
      • Tulsa、Oklahoma、アメリカ
    • Oregon
      • Portland、Oregon、アメリカ
    • Tennessee
      • Germantown、Tennessee、アメリカ
  • イタリア
      • Bologna、イタリア
      • Firenze、イタリア
      • Napoli、イタリア
      • Padova、イタリア
      • Roma、イタリア
      • Rozzano、イタリア
      • San Donato Milanese、イタリア
      • San Giovanni Rotondo、イタリア
    • Foggia
      • San Giovanni Rotondo、Foggia、イタリア
    • Milano
      • Rozzano、Milano、イタリア
      • San Donato Milanese、Milano、イタリア
  • カナダ
    • British Columbia
      • Vancouver、British Columbia、カナダ
      • Victoria、British Columbia、カナダ
    • Nova Scotia
      • Halifax、Nova Scotia、カナダ
    • Ontario
      • London、Ontario、カナダ
      • Vaughan、Ontario、カナダ
  • チェコ
      • Hradec Kralove、チェコ
      • Kladno、チェコ
      • Pardubice、チェコ
      • Praha 10、チェコ
      • Praha 4、チェコ
      • Praha 7、チェコ
  • ハンガリー
      • Bekescsaba、ハンガリー
      • Budapest、ハンガリー
      • Debrecen、ハンガリー
      • Gyongyos、ハンガリー
      • Gyula、ハンガリー
      • Jaszbereny、ハンガリー
      • Kistarcsa、ハンガリー
      • Miskolc、ハンガリー
      • Mosonmagyarovar、ハンガリー
      • Pecs、ハンガリー
      • Szeged、ハンガリー
      • Szekesfehervar、ハンガリー
      • Szekszard、ハンガリー
      • Vac、ハンガリー
  • フランス
      • Lille Cedex、フランス
      • Nantes Cedex 1、フランス
      • Nice Cedex 3、フランス
      • Pessac、フランス
      • Reims、フランス
      • Saint Etienne、フランス
      • Toulouse Cedex 09、フランス
    • Alpes Maritimes
      • Nice Cedex 3、Alpes Maritimes、フランス
    • Gironde
      • Pessac、Gironde、フランス
    • Loire
      • Saint Etienne、Loire、フランス
    • Marne
      • Reims、Marne、フランス
    • Nord
      • Lille cedex、Nord、フランス
  • ベルギー
      • Bonheiden、ベルギー
      • Bruxelles、ベルギー
      • Herentals、ベルギー
      • Kortrijk、ベルギー
      • Leuven、ベルギー
      • Roeselare、ベルギー
  • ポーランド
      • Bialystok、ポーランド
      • Elblag、ポーランド
      • Poznan、ポーランド
      • Warszawa、ポーランド
      • Wroclaw、ポーランド

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年～80年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. Signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has a diagnosis of moderately to severely active Crohn's disease (CD) at least 3 months prior to enrollment, with a Crohn's Disease Activity Index (CDAI) score of 220-450 during the Screening Period, a simple endoscopic score for Crohn's Disease (SES-CD) score of ≥7 and presence of at least one mucosal ulceration documented by recorded ileocolonoscopy at Screening assessed by the central reader.
  4. Has CD with involvement of the ileum and/or colon that can be assessed by ileocolonoscopy.
  5. Is male or female and aged 18 to 80 years, inclusive.
  6. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.
  7. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.

  8. Has demonstrated an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents as defined below:

    • Immunomodulators:

      i. Has signs and symptoms of persistently active disease despite a history of at least one 12-week regimen of oral azathioprine (≥1.5 mg/kg) or 6-mercaptopurine (≥0.75 mg/kg), OR ii. Has a history of intolerance (including but not limited to nausea/vomiting, abdominal pain, pancreatitis, liver function test abnormalities, lymphopenia, thiopurine S-methyltransferase non wild type [where wild type is defined as thiopurine S-methyltransferase (TPMT)*1/*1], infection) to at least 1 immunomodulator.

    • Tumor necrosis factor- alpha (TNF-α) antagonists:

      i. Has signs and symptoms of persistently active disease despite a history of at least 1 induction with:

      1. Infliximab: 4-week regimen of 5 mg/kg, 2 doses at 2 weeks apart, OR
      2. Adalimumab: 2-week regimen of 160 mg on Day 1 and 80 mg on Day 15, OR
      3. Certolizumab: 4-week regimen of 400 mg initially at Weeks 0, 2, 4 OR ii. Has recurrence of symptoms during maintenance dosing following prior clinical benefit (discontinuation despite clinical benefit does not qualify), OR iii. Has a history of intolerance of infliximab, adalimumab, or certolizumab, including but not limited to, infusion-related reaction, demyelination, congestive heart failure, or infection.
    • Corticosteroids i. Signs and symptoms of persistently active disease despite a history of at least one 4-week induction regimen that included a dose equivalent to prednisone 30 mg daily orally for 2 weeks or intravenous(ly) (IV) for 1 week, OR ii. Signs and symptoms of persistently active disease despite treatment with budesonide 9 mg daily or 6 mg daily for maintenance, OR iii. At least one failed attempt to taper corticosteroids to below a dose equivalent to prednisone 10 mg daily orally, OR iv. History of intolerance to corticosteroids (including, but not limited to, Cushing's syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia, and infection).
  9. May be receiving a stable therapeutic dose of conventional therapies for CD (excluding other biologic agents 60 days before enrollment).
  10. Has a family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factors must be up-to-date on colorectal cancer surveillance (may be performed during Screening).

Exclusion Criteria:

  1. Has received a diagnosis of ulcerative colitis or indeterminate colitis.
  2. Has clinical evidence of abdominal abscess.
  3. Has a history of >3 small bowel resections or diagnosis of short bowel syndrome.
  4. Has extensive colonic resection, ie, subtotal or total colectomy with <15 cm colon remaining.
  5. Has ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
  6. Has a history or evidence of adenomatous colonic polyps that have not been removed.
  7. Has a history or evidence of colonic mucosal dysplasia.
  8. Has intolerance or contraindication to undergo ileocolonoscopy.

  9. Has active or latent tuberculosis, regardless of treatment history, as evidenced by any of the following:

    a. History of tuberculosis (TB). b. A diagnostic TB test performed during screening that is positive, as defined by: i. A positive QuantiFERON® test or 2 successive indeterminate QuantiFERON tests OR ii. A tuberculin skin test reaction ≥10 mm (≥5 mm in participants receiving the equivalent of >15 mg/day prednisone).

  10. Has chronic hepatitis B (HBV) or hepatitis C (HCV) infection.
  11. Has any identified congenital or acquired immunodeficiency (eg, common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation).
  12. Has evidence of active C. difficile infection or is having treatment for C. difficile infection or other intestinal pathogens during Screening.
  13. Has evidence of an active infection during Screening.
  14. Currently requires or has a planned surgical intervention for CD during the study.
  15. Has received any investigational compound within 60 days of enrollment.
  16. Has received any biologics within 60 days of enrollment.
  17. Has received any live vaccinations within 30 days prior to enrollment.
  18. Has conditions which, in the opinion of the investigator, may interfere with the participant's ability to comply with the study procedures.
  19. Has any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal (GI), genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise participant safety.
  20. Has a history of hypersensitivity or allergies to vedolizumab or its components.
  21. Has had prior exposure to vedolizumab, natalizumab, efalizumab, or rituximab.
  22. Had a surgical procedure requiring general anesthesia within 30 days prior to screening or is planning to undergo major surgery during the study period.
  23. Has a history of malignancy, except for the following: adequately-treated nonmetastatic basal cell skin cancer; squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to Screening; and history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years prior to screening. Participants with a remote history of malignancy (eg, >10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received and must be discussed with the sponsor on a case-by-case basis prior to enrollment.
  24. Has a history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
  25. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist during Screening or prior to the administration of study drug.

  26. Has any of the following laboratory abnormalities during the Screening Period:

    i. Hemoglobin level <8 g/dL. ii. White blood cell (WBC) count <3*10^9/L. iii. Lymphocyte count <0.5*10^9/L. iv. Platelet count <100*10^9/L or >1200*10^9/L. v. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3*the upper limit of normal (ULN).

    vi. Alkaline phosphatase >3*ULN. vii. Serum creatinine >2*ULN.

  27. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to enrollment.
  28. Has an active psychiatric problem that, in the investigator's opinion, may interfere with compliance with study procedures.
  29. Is unable to attend all the study visits or comply with study procedures.
  30. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 18 weeks after participating in this study; or intending to donate ova during such time period.
  31. If male, the participant intends to donate sperm during the course of this study or for 18 weeks thereafter.
  32. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.

  33. Participants who are at sites participating in the magnetic resonance enterography (MREn) substudy may not participate if they have intolerance or contraindication to the procedure or if any of the following exclusions apply:

    1. Has certain implanted medical devices, such as pacemakers or implantable cardioverter defibrillators (ICDs), or ferromagnetic metallic foreign bodies, such as shrapnel or certain tattoos.
    2. Has allergy to gadolinium-based magnetic resonance (MR) IV contrast agents.
    3. Has known claustrophobia.
    4. Has estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2 at Screening.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：処理
  • 割り当て：なし
  • 介入モデル：単一グループの割り当て
  • マスキング：なし（オープンラベル）

武器と介入

参加者グループ / アーム
介入・治療
実験的：Vedolizumab 300 mg
Part A: Vedolizumab 300 mg, intravenously (IV), once on Day 1 and Weeks 2, 6, 14 and 22, followed by Part B: Vedolizumab 300 mg, intravenously (IV), once at Weeks 30, 38, and 46.
薬：Vedolizumab
Vedolizumab intravenous injection
他の名前：
  • MLN0002

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Part A: Percentage of Participants Achieving Endoscopic Remission at Week 26
時間枠：Week 26
Endoscopic remission is defined as a simple endoscopic score for Crohn's Disease (SES-CD) score of ≤4. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.
Week 26

二次結果の測定

結果測定
メジャーの説明
時間枠
Part A: Percentage of Participants Achieving Complete Mucosal Healing at Week 26
時間枠：Week 26
Complete mucosal healing is defined as absence of ulceration.
Week 26
Part B: Percentage of Participants Achieving Complete Mucosal Healing at Week 52
時間枠：Week 52
Complete mucosal healing is defined as absence of ulceration.
Week 52
Part A: Percentage of Participants Achieving Endoscopic Remission at Week 14
時間枠：Week 14
Endoscopic remission is defined as a SES-CD score of ≤4. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.
Week 14
Part B: Percentage of Participants Achieving Endoscopic Remission at Week 52
時間枠：Week 52
Endoscopic remission is defined as a SES-CD score of ≤4. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.
Week 52
Part A: Percentage of Participants With Endoscopic Response at Week 14
時間枠：Baseline and Week 14
Endoscopic response is defined as a reduction in SES-CD from Baseline by ≥50%. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.
Baseline and Week 14
Part A: Percentage of Participants With Endoscopic Response at Week 26
時間枠：Baseline and Week 26
Endoscopic response is defined as a reduction in SES-CD from Baseline by ≥50%. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.
Baseline and Week 26
Part B: Percentage of Participants With Endoscopic Response at Week 52
時間枠：Baseline and Week 52
Endoscopic response is defined as a reduction in SES-CD from Baseline by ≥50%. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.
Baseline and Week 52
Part A: Percentage of Participants Achieving Clinical Response at Week 10
時間枠：Baseline and Week 10
Clinical response is defined as Crohn's Disease Activity Index (CDAI) decrease from Baseline of ≥100 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.
Baseline and Week 10
Part A: Percentage of Participants Achieving Clinical Response at Week 26
時間枠：Baseline and Week 26
Clinical response is defined as CDAI decrease from Baseline of ≥100 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.
Baseline and Week 26
Part B: Percentage of Participants Achieving Clinical Response at Week 52
時間枠：Baseline and Week 52
Clinical response is defined as CDAI decrease from Baseline of ≥100 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.
Baseline and Week 52
Part A: Percentage of Participants Achieving Clinical Remission at Week 10
時間枠：Week 10
Clinical remission is defined as CDAI score of ≤150 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.
Week 10
Part A: Percentage of Participants Achieving Clinical Remission at Week 26
時間枠：Week 26
Clinical remission is defined as CDAI score of ≤150 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.
Week 26
Part B: Percentage of Participants Achieving Clinical Remission at Week 52
時間枠：Week 52
Clinical remission is defined as CDAI score of ≤150 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.
Week 52
Part B: Percentage of Participants With Durable Clinical Remission
時間枠：Weeks 26 and 52
Durable clinical remission is defined as clinical remission at both Week 26 and Week 52. Clinical remission is defined as CDAI score of ≤150 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The percentage of participants assessed at Week 52 who had clinical remission at Week 26 of Part A and also had clinical remission at Week 52 is reported.
Weeks 26 and 52

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Takeda

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2015年3月30日

一次修了 (実際)

2017年6月2日

研究の完了 (実際)

2018年2月21日

試験登録日

最初に提出

2015年3月26日

QC基準を満たした最初の提出物

2015年4月20日

最初の投稿 (見積もり)

2015年4月23日

学習記録の更新

投稿された最後の更新 (実際)

2018年9月14日

QC基準を満たした最後の更新が送信されました

2018年8月31日

最終確認日

2018年8月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • MLN0002-3028
  • U1111-1159-5806 (レジストリ識別子：WHO)
  • 2014-003509-13 (EudraCT番号)
  • 183974 (レジストリ識別子：HC-CTD)

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する